Literature DB >> 20067560

Platelet von Willebrand factor--structure, function and biological importance.

Rachel T McGrath1, Emily McRae, Owen P Smith, James S O'Donnell.   

Abstract

Besides circulating in normal plasma, von Willebrand factor (VWF) is also stored at relatively high concentration within the alpha-granules of platelets. This pool of platelet VWF exists distinct from plasma VWF, and is enriched in haemostatically-active high molecular weight multimers. Interestingly, the glycosylation profile of platelet VWF differs significantly from that of plasma VWF. Total sialic acid and galactose expression are reduced twofold on platelet VWF, and ABO blood group carbohydrate determinants are not present on the N-linked glycans of platelet VWF. Consequently, in view of the critical role played by VWF glycans in modulating its activity, it is not surprising that the functional properties of platelet VWF differ markedly compared to those of plasma VWF. Nevertheless, animal model studies suggest that both plasma and platelet VWF play important roles in securing primary haemostasis. In addition, platelet VWF antigen and activity levels vary markedly between patients with different types of von Willebrand disease (VWD). Future studies to define the biochemical mechanisms responsible for these differences between plasma and platelet VWF are thus not only of basic scientific interest, but also of direct translational importance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20067560     DOI: 10.1111/j.1365-2141.2009.08052.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  24 in total

1.  Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis.

Authors:  S Kanaji; S A Fahs; Q Shi; S L Haberichter; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

2.  Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.

Authors:  W O Tobin; J A Kinsella; G F Kavanagh; J S O'Donnell; R T McGrath; T Coughlan; D R Collins; D O'Neill; B Egan; S Tierney; T M Feeley; R P Murphy; D J H McCabe
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

3.  Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.

Authors:  Michelle Lavin; Sonia Aguila; Sonja Schneppenheim; Niall Dalton; Kenneth L Jones; Jamie M O'Sullivan; Niamh M O'Connell; Kevin Ryan; Barry White; Mary Byrne; Marie Rafferty; Mairead M Doyle; Margaret Nolan; Roger J S Preston; Ulrich Budde; Paula James; Jorge Di Paola; James S O'Donnell
Journal:  Blood       Date:  2017-09-15       Impact factor: 22.113

4.  Perioperative management of patients with von Willebrand disease.

Authors:  James S O'Donnell; Michelle Lavin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 5.  Historical perspective and future directions in platelet research.

Authors:  B S Coller
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

Review 6.  New treatment approaches to von Willebrand disease.

Authors:  Michelle Lavin; James S O'Donnell
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

7.  The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.

Authors:  Q Shi; J A Schroeder; E L Kuether; R R Montgomery
Journal:  J Thromb Haemost       Date:  2015-06-11       Impact factor: 5.824

8.  Role of RNA splicing in mediating lineage-specific expression of the von Willebrand factor gene in the endothelium.

Authors:  Lei Yuan; Lauren Janes; David Beeler; Katherine C Spokes; Joshua Smith; Dan Li; Shou-Ching Jaminet; Peter Oettgen; William C Aird
Journal:  Blood       Date:  2013-03-25       Impact factor: 22.113

Review 9.  New developments in von Willebrand disease.

Authors:  Helen Fogarty; Dearbhla Doherty; James S O'Donnell
Journal:  Br J Haematol       Date:  2020-05-12       Impact factor: 6.998

Review 10.  Low VWF: insights into pathogenesis, diagnosis, and clinical management.

Authors:  James S O'Donnell
Journal:  Blood Adv       Date:  2020-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.